Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer (Diversity Supplement - Belgodere)
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer (Diversity Supplement - Belgodere)
批准号:
10745843
负责人:
Matthew E. Burow
金额:
$11.02万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-01 至 2026-08-31
关键词:
Antineoplastic AgentsBiological AssayBiological ProcessCell CycleCell LineCellsCellular biologyChemicalsCommunitiesDNA DamageDNA biosynthesisDiabetes MellitusDiseaseDisease ProgressionDrug TargetingEnvironmentEtiologyFDA approvedFamilyFamily memberFree WillHealthHumanIndividualInflammatory Bowel DiseasesLinkMalignant NeoplasmsMeasuresMedicineMitosisMolecularNeuronsOncologyOutputPathologicPathway interactionsPharmaceutical ChemistryPhosphotransferasesPhysiologicalPlayProcessProliferatingProtein FamilyProtein KinaseProteinsProteomeReagentReporterResearchResearch PersonnelResourcesRoleScientistSignal PathwaySignal TransductionSystemcancer therapychronic inflammatory diseaseciliopathycilium biogenesisdrug discoverydruggable targetinhibitorkinase inhibitorknock-downmembermigrationnew therapeutic targetresponsesuccesssupplemental instructiontool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT / PROJECT SUMMARY
Kinases, a class of proteins with more than 500 members in the human proteome, are important regulators of
biological processes in health and disease. Kinases have proven to be excellent drug targets with more than 70
FDA approved medicines that target kinases. Despite this success, most kinases are understudied, and details
of their functions are poorly understood. The NEK family of 11 kinases (NEK1 through NEK11) is a particularly
understudied set of kinases that play roles in key biological processes like the cell cycle, ciliogenesis, and the
DNA damage response (DDR), all with relevance to cancer and human health. These kinases have emerging
links to numerous cancers, diabetes, inflammatory bowel disease, ciliopathies, and ALS. In this project we will
use an efficient kinase systems-based approach to create an enabling suite of chemical probes, assays,
reagents, and molecular tools to identify NEK family members that have key roles in cancer. These high-quality
compounds and reagents we generate, which we will freely share, will allow scientists to build a deep
understanding of the physiological and pathological roles members of the NEK family play. In Aim 1 we will
create potent and selective inhibitors of each NEK using iterative medicinal chemistry and state of the art in cell
target engagement assays. In a complementary effort for this aim we will also create inducible NEK knockdown
cell lines. In Aim 2, using compounds and the NEK knockdown lines, we will evaluate the role and importance of
each NEK in a suite of NEK and oncology-relevant cell health and cell biology signaling assays, measuring
effects on proliferation, migration, the cell-cycle, DNA replication, and ciliogenesis. In Aim 3 we will
experimentally determine the substrates of each NEK, locate the NEKs in broader kinase-dependent signaling
pathways, and develop genetically targetable kinase activity reporters for tracking NEK activity within the
endogenous cellular environment. Output from this project will include potent and selective NEK inhibitors, NEK
family-wide assays, details on the impact of NEK inhibition and knockdown on key cancer processes, molecular
tools, and NEK substrate and pathway information. Successful completion will provide a framework and the
resources needed to validate individual NEKs as high quality, druggable targets for the treatment of cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer
-
批准号:10503430
-
项目类别:
-
资助金额:$63.61万
-
财政年份:2022
-
负责人:Matthew E. Burow
-
依托单位:
Characterization of an understudied kinase, NEK5, in acquisition of a mesenchymaland migratory cell phenotype
-
批准号:10047560
-
项目类别:
-
资助金额:$16.68万
-
财政年份:2020
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8463129
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8260576
-
项目类别:
-
资助金额:$30.1万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:7987895
-
项目类别:
-
资助金额:$32.24万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8082806
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8660659
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:7163550
-
项目类别:
-
资助金额:$28.16万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6849312
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6993557
-
项目类别:
-
资助金额:$29.0万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:7344925
-
项目类别:
-
资助金额:$6.56万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:7330340
-
项目类别:
-
资助金额:$27.6万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6612489
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6706387
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
海外基金